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Background 
It is not known whether regional brain N-acetyl aspartate (NAA) changes in the 
progression from prodrome to chronic schizophrenia. We used effect size meta-
analysis to determine which brain regions show the most robust reductions in NAA 
first episode and chronic schizophrenia as measured by proton magnetic resonance 
spectroscopy (1H-MRS), and to determine whether these changes are present in 
individuals at high risk of developing schizophrenia. 
Methods 
We identified 131 papers of which 97 met inclusion criteria. Data were separated by 
stage of illness (at risk, first episode schizophrenia, chronic schizophrenia) and by 
brain region. For each region, mean and standard deviation of the NAA measure was 
extracted. 
Results 
Significant reductions in NAA levels were found in frontal lobe, temporal lobe and 
thalamus in both patient groups (effect size > 0.3; p<0.01). In individuals at high risk 
of schizophrenia (of whom approximately 20% would be expected to undergo 
transition to psychosis), significant NAA reductions were present in thalamus (effect 
size = 0.78; p<0.05), with reductions at trend level only in temporal lobe (effect size = 
0.32; p<0.1), and no reductions in frontal lobe (effect size = 0.05; p=0.5). 
Conclusions  
These data suggest that schizophrenia is associated with loss of neuronal integrity in 
frontal and temporal cortices and in the thalamus, and suggest that these changes in 
the frontal and temporal lobe may occur in the transition between the at-risk phase 
and the first episode. 
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Introduction 
Proton magnetic resonance spectroscopy (1H-MRS) studies in patients with 
schizophrenia have frequently reported regional reductions in N-acetyl aspartate 
(NAA), a brain metabolite present at very high concentrations in neurons in the CNS. 
Reductions in NAA levels measured by 1H-MRS are associated with ischemic brain 
injury and dementia, leading to the suggestion that NAA represents a surrogate 
marker of neuronal integrity (1). NAA also plays a role in myelin lipid synthesis, the 
control of osmolality, energy metabolism and neurotransmission (through the 
synthesis of NAAG by combination with glutamate) (1). An earlier meta-analysis, by 
Steen and colleagues, of frontal and medial temporal lobe 1H-MRS findings in 
patients with schizophrenia and first episode schizophrenia (FES) revealed that NAA 
levels were reduced in both regions, but that there was not any difference between 
FES and chronic schizophrenia (2).  
 
Recent years have seen an explosion of interest in the prodrome of schizophrenia, 
with many groups studying individuals with attenuated psychotic symptoms and 
people at risk of schizophrenia due to their family history. Of course, only a 
proportion of these individuals eventually go on to develop schizophrenia (3). 
Nonetheless, several MRI studies have shown that people at risk of developing 
schizophrenia have alterations in gray matter volume compared to healthy controls (4-
6), and that they have further reductions in gray matter volume associated with 
transition to psychosis (5). 
 
Reductions in NAA reported in 1H-MRS studies of individuals at risk of 
schizophrenia suggest that these grey matter changes may have a neuronal basis (7), 
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perhaps representing the loss of dendritic arborization that has been reported in 
schizophrenia (8). It should be noted that not all 1H-MRS measures in people at risk 
of schizophrenia have been in agreement (9-10). Given the wide variance with 1H-
MRS, and the requirement for relatively large sample sizes to obtain data with 
reasonable power (11), this is not altogether surprising.  
 
Here, using a meta-analysis of the current literature, we test the hypothesis that 
regional reductions in NAA are associated with illness progression. We hypothesize 
that NAA reductions are most marked in patients with chronic schizophrenia, and are 
less evident in individuals with FES and in individuals at risk of schizophrenia. 
 
Methods 
Selection of studies 
We selected all English-language studies published (or made available electronically) 
before 31
st
 August 2009, of proton spectroscopy in patients with schizophrenia and 
individuals at high risk of schizophrenia compared to normal controls. We employed 
a search strategy using PubMed with keywords “MRS” and one of “schizophrenia”, 
“psychosis”, “UHR”, “ARMS”, “ultra high risk”, “prodromal”, “prodrome” or 
“schizoaffective”, obtaining hard-copies of all papers reporting NAA levels in 
patients with schizophrenia. We also obtained all papers referenced in two previous 
systematic reviews of the field (12-13). We selected all papers reporting mean and 
standard deviation for NAA in patients with schizophrenia, FES, and high risk of 
schizophrenia with a matched control group. Where mean and/or standard deviations 
for NAA were not reported, the authors of the papers were contacted. Efforts were 
made not to double-count subject data – papers in which this was suspected to have 
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occurred were excluded from the analysis. 
 
Methodological considerations 
Analysis of proton magnetic resonance spectroscopy data is complicated by the fact 
that the brain chemicals detected by 1H-MRS (termed metabolites) occur in grey and 
white matter but not in CSF. If the area from which the spectrum is acquired (voxel) 
contains a large percentage of CSF, the estimated metabolite concentrations measured 
using 1H-MRS will underestimate their actual concentration in brain tissue (14).  
 
There are two methods commonly used to correct for this problem. The first is to 
report a ratio of the metabolite of interest to one of the other metabolites that are 
thought to remain relatively constant (either creatine - Cr, or less commonly choline -
Cho). This has the potential drawback that if Cr or Cho levels are altered by illness 
state, the resultant ratio will be affected. The second method is to correct metabolite 
measures (either water-scaled or “absolute”) for the amount of CSF and brain tissue in 
the voxel by dividing the metabolite measure by the percent tissue volume in the 
voxel, sometimes with a further correction made for the relative grey and white matter 
content of the voxel (voxel brain tissue corrected) (14). 
 
The fact that there are different methods for correcting 1H-MRS data for voxel brain 
tissue content makes combination of papers in a meta-analysis problematic. However, 
NAA results using scaled to Cr measures and voxel brain tissue corrected values were 
not found to differ significantly when analysed separately by Steen and colleagues 
(2). They combined data from studies using different methods by calculating the ratio 
of patient to control NAA levels (regardless of voxel tissue correction method). Here, 
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rather than calculate a ratio for each study, we performed a meta-analysis of effect 
size derived from each study, calculated from the absolute mean and SD values for 
patients and controls regardless of outcome method. 
 
Proton magnetic resonance spectroscopy studies require selection of the voxel for 
spectrum acquisition at the time of scanning. Many studies in patients with 
schizophrenia and in individuals at high risk of schizophrenia acquire spectra from 
slightly different brain regions, leading to difficulties in comparing findings. Steen 
and colleagues combined 1H-MRS data acquired from all frontal and all temporal 
lobe regions into two main brain regions. Although this approach could mask findings 
that are specific to a particular subregion of frontal or temporal cortices, they found 
that regardless of subregion chosen, the NAA findings were similar within each 
overall region. We took a similar approach, combining NAA findings into seven 
regions – frontal lobe, temporal lobe, thalamus, cerebellum, parietal lobe, occipital 
lobe and basal ganglia. 
 
Identification of individuals at high risk of schizophrenia 
There are two current methods of identifying individuals at high risk of schizophrenia. 
The first is to identify teenage relatives of patients with schizophrenia (high genetic 
risk of schizophrenia), and the second is to select subjects on the basis of their clinical 
presentation – either having attenuated (subthreshold) psychotic symptoms, or a brief 
(less than 7 day) psychotic episode, which resolved without intervention (“BLIP”), 
so-called ultra high risk (UHR) patients (15). In the present study, we included both 
high risk groups. 
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Identifying individuals with First Episode Schizophrenia 
Criteria for FES were not explicitly reported in any of the studies identified. Where 
authors reported the research subjects as being FES they were included as such for the 
purposes of the present analysis. We also included subjects reported as having 
schizophreniform disorder. Studies that included patients with non-schizophrenic 
psychosis were excluded from the analysis unless data from the patients with FES 
could be extracted. 
  
Analysis 
Data were separated by phase of illness (at risk of schizophrenia, FES, chronic 
schizophrenia), and by brain region (thalamus, basal ganglia, cerebellum, parietal 
lobe, occipital lobe, temporal lobe, frontal lobe). Where a study reported measures 
from more than one subregion (e.g. anterior cingulate cortex and DLPFC), these were 
entered into the appropriate meta-analysis (i.e. frontal lobe) as two (or more) 
independent datasets. Studies reporting metabolite values from different brain 
hemispheres, different subdivisions of patients (within each broad group of at risk, 
FES and chronic schizophrenia), or different outcome measures were treated in the 
same manner. Sample sizes for both patients and controls were adjusted to ensure that 
participants in such studies were not double-counted. This is an accepted strategy for 
handling such data (16). 
 
We conducted a meta-analysis of effect size, using the meta (version 1.5-0) and 
metafor (version 1.1-0) packages for the R statistical programming language (17). A 
random effects model was used for the analyses, as it was considered likely that 
variation in subregion, hemisphere, and choice of outcome measure could potentially 
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introduce significant heterogeneity (18). The standardized mean difference (SMD) 
effect size (Hedge’s g) was calculated for each study and combined as a weighted 
mean by the inverse variance method. 
 
Meta-regression was used to test the hypothesis that the degree of reduction in NAA 
levels relative to healthy controls would increase with illness phase from risk of 
developing psychosis to chronic schizophrenia. Where evidence for such a 
relationship was found, the timing of these NAA losses was examined using further 
meta-regressions. 
 
Publication bias 
Publication bias was investigated qualitatively using funnel plots for each group and 
brain region. Funnel plot asymmetry was assessed quantitatively by linear regression 
analysis(19) and the Duval and Tweedie trim and fill procedure (20).  
 
Analysis of heterogeneity 
Cochran Q and I
2
 statistics were calculated in order to evaluate within study 
heterogeneity. Meta-regression of experimental variables was performed to 
investigate possible sources of heterogeneity, including effects of laterality, echo 
time, 1H-MRS acquisition technique (PRESS, STEAM), outcome measure (scaled to 
creatine vs. voxel brain tissue correction) and subregion. The influences of important 
demographic and clinical variables (age, age of onset, genetic vs. clinical at risk 
group, duration of medication and PANSS subscales) were investigated using meta-
regression. It was not possible to compare NAA levels in patients treated with typical 
vs. atypical antipsychotics using meta-regression as most studies did not report 
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metabolite values for these treatment groups separately. Results were corrected for 
multiple comparisons using the Holm-Bonferroni method, in order to guard against 
type I errors (21). 
 
Outliers and sensitivity analysis 
Where significant heterogeneity was found the papers contributing to this were 
identified by visual inspection and cumulative meta-analysis. Outliers were examined 
in order to determine possible explanations for their results. We then repeated the 
meta-analyses with the outliers excluded, in order to assess the extent to which their 
findings were dependent upon the influence of such outliers. 
 
To investigate the effect of our use of a random effects meta-analysis, we reanalyzed 
the data using fixed effects meta-analysis. 
 
Lastly, to investigate the effect of treating multiple results from a single study as 
separate dataset, we repeated the meta-analyses using a single ‘composite’ measure 
from each study: where studies reported results from different subregions or using 
different outcome measures in the same paper, these were combined into a single 
value and analyzed using a random effects meta-analysis.  
 
Results 
Study selection 
The literature search described above yielded 269 papers, of which 131 were 
potentially suitable for this study. Of these, 12 papers were excluded because of 
overlapping or suspected overlapping data with other papers from the same research 
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group. Eleven were excluded for lack of a control group. Six were excluded because 
mean and standard deviation of NAA levels were not reported and 5 were excluded as 
it was impossible to separate patients with schizophrenia from those with other 
diagnoses. A total of 97 papers met the inclusion criteria and were thus included in 
further analysis (7, 9-10, 22-115). 
 
NAA measures by region and illness phase 
Frontal lobe 
In keeping with previous reports, NAA in frontal lobe was significantly reduced 
compared to controls in patients with chronic (fig. 1) and FES (fig. 2). No significant 
reduction in NAA was found in individuals at high risk of schizophrenia, whether due 
to a genetic or clinical risk (figure 3). 
 
Temporal lobe 
NAA in temporal lobe was reduced significantly in patients with chronic (fig. 4) and 
FES (fig. 5). In individuals at risk of developing schizophrenia, a reduction at trend 
level was found, although the effect size was comparable to that reported FES and 
chronic groups (fig. 6). 
 
Thalamus 
Significant NAA reductions in thalamus were present in patients with chronic 
schizophrenia (fig. 7) and in patients with first-episode schizophrenia (fig. 8). Only 
two studies measuring NAA in thalamus in individuals at high risk of schizophrenia 
have been published to date, but both showed a significant reduction compared to 
healthy controls (table 1). 
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Other regions 
One group reported significant reductions in NAA in patients with chronic 
schizophrenia, FES, and in individuals with an at risk mental state in corpus callosum 
(113-114). There are no replications of these data by other groups at present. 
 
Studies reporting NAA data in basal ganglia, cerebellum, parietal and occipital lobe 
have been published in patients with chronic schizophrenia and FES. 
 
A trend for lower NAA in cerebellum compared to healthy controls was found in 
studies of first episode and chronic schizophrenia, becoming significant when the two 
groups were combined (table 1). There was no evidence for a reduction in basal 
ganglia NAA levels in patients with chronic or first-episode schizophrenia (table 1). A 
single study examining the basal ganglia in individuals at risk of developing 
schizophrenia has been published, although its results are non-significant (24). Pooled 
results of studies examining patients with both first-episode and chronic 
schizophrenia, either taken separately or combined, found no evidence for a reduction 
in NAA levels in occipital or parietal lobe (table 1). 
 
Difference in NAA measures with stage of illness  
A statistically significant difference in NAA levels with illness phase was found in 
frontal lobe only, with NAA reductions being present in FES patients but not in the at 
risk group (table 2). No significant differences in NAA levels were found in the 
patients with first episode compared to chronic schizophrenia. 
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Publication Bias 
Funnel plots revealed no obvious signs of publication bias for any phase of illness or 
region (see supplemental materials eFigures 1-7). The linear regression test for funnel 
plot asymmetry confirmed this finding for all regions except frontal lobe, where a 
trend towards asymmetry was found for patients with chronic schizophrenia (Table 
2). However, the trim and fill procedure estimated the number of missing studies to be 
zero. It was therefore considered unlikely that significant publication bias existed. 
 
Heterogeneity 
Significant heterogeneity was found in frontal lobe for all phases of illness. In 
temporal lobe significant heterogeneity was found for patients with first-episode 
schizophrenia and chronic schizophrenia but not for individuals at increased risk of 
developing schizophrenia (table 3). 
 
Meta-regression 
This meta-analysis included studies of two different categories of individuals 
considered to be at heightened risk of developing schizophrenia – those related to 
patients diagnosed with schizophrenia and those experiencing prodromal symptoms of 
schizophrenia. Meta-regression revealed no significant effect of these categories on 
NAA levels. Furthermore, no significant effect of hemisphere or variation in frontal 
lobe subregion was found for any patient group (Table 3), in line with previous 
findings (116). We therefore felt justified in our decision to include results from both 
hemispheres and from different frontal subregions in a single analysis. In temporal 
lobe an effect of outcome measure (ratio to Cr vs. voxel brain tissue correction) was 
found (uncorrected p<0.5) for both patients with FES and individuals at risk of 
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schizophrenia, with studies employing ratio to Cr reporting a greater effect size, 
although this was not statistically significant after correction for multiple comparisons 
(table 4). 
 
One significant effect was found for chronic patients: that of negative symptoms (as 
measured by PANSS) on NAA levels in the temporal lobe (with lower NAA being 
associated with higher levels of negative symptoms). For first episode patients, in 
frontal lobe, significant effects of age of onset of illness (lower NAA with earlier 
onset) and duration of antipsychotic treatment (lower NAA with longer duration of 
treatment) on NAA levels were found (table 4). No effect was found for duration of 
illness on NAA levels, however. The complete results of the meta-regression are 
presented as supplemental material (eTable 2). 
 
Outliers and sensitivity analysis 
Although there was a high overall degree of consistency between findings, there were 
a number of outliers which we considered individually. 
 
Frontal Lobe  
The study by Wood and colleagues (10), emerged as a significant outlier in the 
analysis of the frontal lobe in individuals at risk of schizophrenia. The authors note 
that this increase in NAA/Cr ratio might be due to a reduction in Cr levels, 
representing hypometabolism, although other groups have not replicated this finding. 
 
The study of FES patients by Yasukawa and colleagues was a significant outlier in 
frontal lobe NAA measures (89). This particular study reported results two patient 
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groups: one containing patients diagnosed with Gilbert’s syndrome (the outlying 
result); the other patients who did not have this condition. 
 
In patients with chronic schizophrenia, Sanches and colleagues (71), reported a 
markedly greater effect size for NAA reduction in frontal lobe in patients, whilst 
Tebartz van Elst and colleagues, reported a marked increase in NAA in patients in this 
brain region (80). The reason for these discrepancies is not clear, but Sanches and 
colleagues employed a ratio to creatine plus choline for their measurement of NAA, a 
measure rarely used by other groups. The paper by Tebartz van Elst has been 
criticized for failing to employ adequate quality control of acquired magnetic 
resonance spectra for the reliable measurement of glutamate (117), and it is possible 
that this may have contributed to the difference in their reported data. 
 
Temporal lobe 
The same group that studied NAA in FES patients with Gilbert’s syndrome in frontal 
lobe reported data from temporal lobe in a separate paper (33). This result was 
similarly the only outlier for this region and patient group. 
 
For chronic patients, the only outlier in temporal lobe was the left hemisphere 
subgroup from Maier and colleagues (99). One possible explanation is that the 
patients and controls in this study were not well matched in terms of age; the patients 
being significantly older. Age-related reductions in hippocampal NAA levels have 
been reported in healthy subjects (118-119), and it seems plausible that these should 
also occur to at least the same degree in patients with schizophrenia. However, it is 
not clear why this would affect only the left hippocampus.  
15 
 
 
 
 
Other regions 
In thalamus, one subgroup of Heimburg and colleagues (32), was identified as an 
outlier in the chronic group. It is likely that its outlier status is due to its diminutive 
size – only two patients. 
 
Removal of outliers 
Meta-analyses were repeated with outliers excluded. In most cases the result was a 
slight reduction in the magnitude of the effect size but not to a degree that alters the 
findings of this study (table 5). The exception to this is for first episode patients in 
temporal lobe. Here, the result of removing the outlying study was to reduce the effect 
size to trend level. 
 
Repeating the analyses using a single composite measure for each study yielded no 
significant differences in outcomes for any region. Likewise, there were no significant 
differences in effect sizes when the analyses were carried out using a fixed effects 
model (table 5). 
 
Discussion 
This is the first meta-analysis of 1H-MRS data comparing regional findings in 
patients with chronic, first episode and genetic and clinical risk of schizophrenia. We 
found that there was little difference in NAA findings in FES and chronic 
schizophrenia. In both groups, reduced NAA levels compared to controls were found 
in frontal lobe, temporal lobe and thalamus. The degree of reduction did not differ 
significantly between patients with FES and chronic schizophrenia, suggesting a lack 
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of progression. In individuals at risk of schizophrenia, whether due to genetic risk or 
subthreshold clinical features of schizophrenia, reductions in NAA were not present 
in frontal lobe. As discussed above, many of these individuals would not go on to 
develop schizophrenia (3), and so results in this group are likely to be significantly 
diluted.  
 
The most robust differences in NAA levels in individuals at risk of schizophrenia 
compared to controls were found in thalamus. Relative NAA reductions in temporal 
lobe were present only at trend level (although this may have been due to the lower 
power in the at risk group), and NAA levels in frontal lobe did not differ significantly 
from controls. Taken together, these findings suggest that NAA reductions in 
thalamus, and possibly in corpus callosum, may be a trait marker of schizophrenia 
risk, or, alternatively, may be the first regions to be affected by the illness. 
 
As longitudinal data about which of the at risk individuals went on to develop a first 
episode of schizophrenia were not reported, it is not possible to determine the reason 
that reduced NAA levels were not present in frontal lobe, and were present at trend 
level only in temporal lobe. It is possible to speculate that NAA reductions in these 
regions might occur only with transition to psychosis, mirroring findings in gray 
matter change (5). Alternatively, reductions in NAA levels may already have occurred 
in these regions but only those individuals destined to develop psychosis.  
 
Another possibility for differences in temporal lobe measures is suggested by the 
meta-regression. The magnitude of the NAA reduction in the temporal lobe for 
patients with FES was greater in studies using ratio to Cr as an outcome measure than 
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in those employing voxel brain tissue correction. The same pattern is seen for at-risk 
individuals. The reason for this finding is not clear, but it is possible temporal lobe 
creatine levels were increased in these groups. There is some evidence to support 
increased hippocampal activity as a possible mechanism in the early stages of 
schizophrenia (121-122), which could conceivably be associated with increased 
hippocampal creatine levels (a marker of cellular metabolism). Thus, significant 
reductions in temporal lobe NAA may arise only in the later stages of illness, with 
increased metabolism, as indicated by increased creatine levels, occurring earlier. 
There is a need for well-designed longitudinal studies to answer this question. 
 
This study provides the first evidence of a significant correlation between negative 
symptoms and temporal lobe NAA levels in patients with chronic schizophrenia. 
Correlations between severity of negative symptoms and NAA levels have been 
observed before, notably in frontal lobe (78, 88). Given the suggested close 
relationship between NAA and glutamatergic neurotransmission (123), the current 
finding fits with previous reports of negative symptoms correlating with measures of 
abnormal glutamatergic transmission in hippocampus and temporal lobe (124-125). 
  
This study indicates that an earlier age of onset is associated with lower frontal NAA 
levels in individuals with FES, supporting the hypothesis that an earlier age of onset 
may be associated with a more severe illness and more marked anatomical changes 
(126-127). The study also indicates that antipsychotic exposure is associated with 
reduced frontal NAA levels in FES patients. This finding is in keeping with earlier 
studies which have reported correlations between duration of treatment with typical 
antipsychotic medication and low NAA levels in this region (particularly anterior 
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cingulate cortex), while atypical neuroleptics appear to be associated with less of a 
reduction and perhaps even an increase in NAA levels (56, 128-130). No significant 
effect was found for duration of illness, supporting the hypothesis that NAA 
reductions are not progressive in schizophrenia. 
 
Weaknesses 
There are a number of shortcomings and potential weaknesses of this study that we 
acknowledge. The combination of results from different sub-regions, into a single 
analysis may have obscured some findings. This was a relatively unavoidable 
problem, given that different research groups use different a-priori regions of interest. 
A previous study did not find any significant differences in NAA changes in sub-
regions (12), and we attempted to address this issue by analyzing these data using 
meta-regression. We did not find any evidence of significant differences in findings 
between different frontal subregions, nor between left and right hemispheres, and so 
feel that the inclusion of these data in a single analysis was justified. We cannot, 
however, exclude the possibility that some laterality or subregional effects in NAA 
levels may exist in the three groups. 
 
Similarly, by including studies reporting different outcome measures in a single 
analysis, we were potentially obscuring other subtle effects. While meta-regression 
did not uncover any systematic influence of outcome measure, a near-significant 
effect was found in temporal lobe for first episode patients. In these groups, 
significantly lower NAA compared to controls was found only with scaled to 
metabolite measures. It is possible that this reflects increased temporal lobe creatine 
levels. It is not known whether or to what extent alterations in creatine levels in other 
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studies have affected the results. 
 
Conclusions 
These data suggest that schizophrenia is associated with reductions in neuronal 
integrity in frontal and temporal lobe and in the thalamus. Preliminary findings 
suggest that the first regions to be affected by loss of NAA in psychotic illness may 
be the thalamus, and possibly the corpus callosum. Further studies examining 
longitudinal changes in NAA in individuals at risk of schizophrenia are required to 
investigate this hypothesis. 
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Figure 1: Forest plot (random effects meta-analysis) of frontal cortex NAA levels in 
patients with chronic schizophrenia compared to 
controls.
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Figure 2: Forest plot (random effects meta-analysis) of frontal cortex NAA levels in 
patients with first episode psychosis compared to controls. 
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Figure 3: Forest plot (random effects meta-analysis) of frontal cortex NAA levels in 
individuals at high risk of psychosis compared to controls. 
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Figure 4: Forest plot (random effects meta-analysis) of temporal cortex NAA levels in 
patients with chronic schizophrenia compared to controls. 
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Figure 5: Forest plot (random effects meta-analysis) of temporal cortex NAA levels in 
patients with first episode psychosis compared to controls. 
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Figure 6: Forest plot (random effects meta-analysis) of temporal cortex NAA levels in 
individuals at high risk of psychosis compared to controls. 
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Figure 7: Forest plot (random effects meta-analysis) of thalamic NAA levels in 
patients with chronic schizophrenia compared to controls. 
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Figure 8: Forest plot (random effects meta-analysis) of thalamic NAA levels in 
patients with first episode psychosis compared to controls. 
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Table 1: Effect size by region for individuals at risk of psychosis (At risk), patients 
with first-episode schizophrenia (FES), chronic schizophrenia (Chronic), and for both 
patient groups combined (All pts). Studies reporting multiple regions or outcome 
measures were entered as separate datasets, with sample sizes adjusted where 
necessary to ensure that participants were not double-counted. 
Region Phase 
No. 
Studies 
No. 
Separate 
Datasets 
No. 
Patients 
No. 
Controls 
Effect 
Size 
Effect Size 
P Value 
Frontal At risk 10 17 212 203 0.05 0.7995 
  FES 19 32 376 428 -0.45 < 0.0001 
  Chronic 41 71 880 799 -0.45 < 0.0001 
  All pts 61* 104* 1279 1256 -0.45 < 0.0001 
Temporal At risk 4 5 82 100 -0.38 0.0703 
  FES 11 19 232 189 -0.53 0.0025 
  Chronic 22 35 524 530 -0.60 < 0.0001 
  All pts 33 54 756 719 -0.58 < 0.0001 
Thalamus At risk 2 3 49 49 -0.72 0.0006 
  FES 5 8 102 88 -0.40 0.0203 
  Chronic 12 20 291 255 -0.32 0.0041 
  All pts 17 28 393 313 -0.34 0.0002 
Basal 
Ganglia FES 
6 9 125 91 
-0.09 0.599 
  Chronic 11 17 200 181 -0.07 0.4981 
  All pts 17 26 325 272 -0.09 0.3195 
Cerebellum All pts 5 6 108 75 -0.50 0.0114 
Occipital All pts 7 11 127 132 0.06 0.6397 
Parietal All pts 5 10 92 83 -0.08 0.6233 
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Table 2: Differences in regional NAA between illness phase as determined using meta-regression (* p<0.05) for individuals at risk of psychosis 
(At risk), patients with first-episode schizophrenia (FES), chronic schizophrenia (Chronic). 
Region All phases 
 
At-risk v. FES 
 
At-risk v. Chronic 
 
FES v. Chronic 
 
 
QM(df=1) P-value QM(df=1) P-value QM(df=1) P-value QM(df=1) P-value 
Frontal 4.0544 0.0441* 6.1078 0.0135* 5.4019 0.0201* 0.0028 0.9577 
Temporal 1.0072 0.3156 
      Thalamus 1.7934 0.1805 
      Basal 
Ganglia 1.1202 0.2899 
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Table 3: Measures of heterogeneity (Cochran Q and I
2
), and estimates of publication 
bias (* p<0.05) for individuals at risk of psychosis (At risk), patients with first-
episode schizophrenia (FES), chronic schizophrenia (Chronic), and for both patient 
groups combined (All pts). 
Region Phase Q df Q P Value I2 (%) 
Publication 
bias t(df) 
Frontal At risk 50.71 16 < 0.0001 68.4 -0.868(15) 
  FES 60.76 31 0.0011 49 -0.531(30) 
  Chronic 209.76 70 < 0.0001 66.6 -1.836(69)* 
  All pts 271.26 103 < 0.0001 62 -1.709(102)* 
Temporal At risk 7.08 4 0.132 43.5 -0.558(3) 
  FES 48.11 18 0.0001 62.6 -0.381(17) 
  Chronic 110.73 34 < 0.0001 69.3 0.075(33) 
  All pts 159.39 53 < 0.0001 66.7 0.051(52) 
Thalamus At risk 1.83 2 0.3998 0 0.446(1) 
  FES 9.05 7 0.2491 22.7 -0.789(6) 
  Chronic 25.67 19 0.1398 26 0.801(18) 
  All pts 34.89 27 0.1418 22.6 0.405(26) 
Basal Ganglia FES 10.56 8 0.2281 24.2 1.089(7) 
  Chronic 13.58 16 0.6301 0 0.858(15) 
  All pts 24.18 25 0.509 0 1.305(24) 
Cerebellum All pts 7.72 5 0.1725 35.2 1.011(1) 
Occipital All pts 10.21 10 0.4223 2 1.939(4) 
Parietal All pts 2.83 9 0.9707 0 -0.560(4) 
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Table 4: Significant modifiers of NAA levels by region and illness phase, as 
determined using meta-regression. Significance (p) values are presented both as raw 
values and as values corrected for multiple comparisons (* corrected p<0.1; ** 
corrected p<0.05). 
 
region phase modifier intercept co-efficient P-value Adjusted P-value (BH) 
Frontal FES Treatment duration -0.3261424 -0.656463833 0.000181 0.01269461 ** 
Frontal FES Age of onset -4.3600038 0.175791899 0.001226 0.02942189 ** 
Frontal FES Overall symptoms (PANSS) -2.7258645 0.028745427 0.004484 0.08070678 * 
Frontal Chr Age of onset -5.4310586 0.22006038 0.021902 0.19711422 
Temporal At risk Outcome measure 0.6180435 -0.65117903 0.03494 0.23579182 
Temporal FES Outcome measure 0.7288 -0.7386 0.0064 0.09216 * 
Temporal FES Age 1.3257 -0.0701 0.012186 0.14622605 
Temporal Chr Negative symptoms (PANSS) 3.1049593 -0.150365854 0.000353 0.01269461 ** 
Temporal Chr Overall symptoms (PANSS) 3.5703324 -0.050596849 0.020307 0.19711422 
Temporal Chr Positive Symptoms (PANSS) 4.9573865 -0.359261152 0.030048 0.23579182 
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Table 5: Comparison of effect size by region and illness phase when combining all 
data from each paper into one composite measure (“combined”), when using a 
fixed effects meta-analysis (“fixed”) and when removing outliers (“outliers 
removed”) 
 
Region Phase 
Combined 
effect size 
Combined 
effect size 
P-value 
Fixed 
effect 
size 
Fixed 
effect 
size p-
value 
Outliers 
removed 
effect 
size 
Outliers 
removed 
effect 
size p-
value 
Frontal At risk 0.12 0.25 0.0495 0.7995 -0.0628 0.6587 
  FES -0.42 < 0.0001 -0.4474 < 0.0001 -0.3883 < 0.0001 
  Chronic -0.39 < 0.0001 -0.4489 < 0.0001 -0.4046 < 0.0001 
Temporal At risk -0.36 0.02 -0.3816 0.0703     
  FES -0.46 0.01 -0.5325 0.0025 -0.253 0.0694 
  Chronic -0.61 < 0.0001 -0.6008 < 0.0001 -0.4948 < 0.0001 
Thalamus At risk -0.72 0.00 -0.7198 0.0006     
  FES -0.39 0.01 -0.4048 0.0203     
  Chronic -0.32 0.00 -0.3174 0.0041 -0.3468 0.0002 
Basal Ganglia FES -0.11 0.45 -0.0884 0.599     
  Chronic -0.07 0.50 -0.0718 0.4981     
Cerebellum All pts -0.49 0.00 -0.4989 0.0114     
Occipital All pts 0.06 0.65 0.0606 0.6397     
Parietal All pts -0.08 0.62 -0.0779 0.6233     
 
